Malta - English - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - ceftazidime pentahydrate - powder for solution for infusion or injection - ceftazidime pentahydrate 1.165 g - antibacterials for systemic use

Malta - English - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2.330 g - antibacterials for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile);   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile);   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftazidime pentahydrate 1.16 g equivalent to ceftazidime 1g - powder for injection - 1 g - active: ceftazidime pentahydrate 1.16 g equivalent to ceftazidime 1g excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: - severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g - powder for injection - 2 g - active: ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: - severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - ceftazidime pentahydrate 582,4 mg - eq. ceftazidime 500 mg - powder for solution for injection - 500 mg - ceftazidime pentahydrate - ceftazidime

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - ceftazidime pentahydrate 1164,8 mg - eq. ceftazidime 1000 mg - powder for solution for injection - 1000 mg - ceftazidime pentahydrate - ceftazidime

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - ceftazidime pentahydrate 2329,6 mg - eq. ceftazidime 2000 mg - powder for solution for injection/infusion - 2000 mg - ceftazidime pentahydrate - ceftazidime

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ceftazidime pentahydrate 1,164 g - eq. ceftazidime 1000 mg - powder for solution for injection/infusion - 1 g - ceftazidime pentahydrate - ceftazidime